The role of epigenetic events in genotoxic hepatocarcinogenesis induced by 2-acetylaminofluorene

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 722, Issue 2, 2011, Pages 106-113

  Pogribny, Igor P ^a   Muskhelishvili, Levan ^a   Tryndyak, Volodymyr P ^a   Beland, Frederick A ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

2 Acetylaminofluorene; Epigenetics; Liver carcinogenesis; MicroRNA; Rat

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOSINE; HISTONE H3; HISTONE H3 LYSINE 27; HISTONE H3 LYSINE 9; HISTONE LYSINE METHYLTRANSFERASE; MICRORNA; N (2 FLUORENYL)ACETAMIDE; PROTEIN CX26; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SUPPRESSOR OF CYTOKINE SIGNALING 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CPG ISLAND; DISEASE MODEL; DNA METHYLATION; EPIGENETICS; GENE AMPLIFICATION; GENOTOXICITY; HISTONE METHYLATION; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; MALE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

2-ACETYLAMINOFLUORENE; ANIMALS; APOPTOSIS; CELL PROLIFERATION; DNA DAMAGE; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICRORNAS; MUTAGENS; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 79957859809     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2010.02.011     Document Type: Article

References (57)

1. Wild C.P. Environmental exposure in cancer epidemiology. Mutagenesis 2009, 24:117-125.
2. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
3. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
4. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
5. Hussain S.P., Schwank J., Staib F., Wang X.W., Harris C.C. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007, 26:2166-2176.
6. Poirier M.C. Chemical-induced DNA damage and human cancer risk. Nat. Rev. Cancer 2004, 4:630-637.
7. Phillips D.H. DNA adducts as markers of exposure and risk. Mutat. Res. 2005, 577:284-292.
8. Rundle A. Carcinogen-DNA adducts as biomarker for cancer risk. Mutat. Res. 2006, 600:23-36.
9. Luch A. Nature and nurture-lessons from chemical carcinogenesis. Nat. Rev. Cancer 2005, 5:113-125.
10. Loeb L.A., Harris C.C. Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res. 2008, 68:6863-6872.
11. Pitot H.C. Adventures in hepatocarcinogenesis. Annu. Rev. Pathol. 2007, 2:1-29.
12. 1 and polycyclic aromatic hydrocarbon adducts, p53 mutations and p16 methylation in liver tissue and plasma of hepatocellular carcinoma patients. Int. J. Cancer 2006, 119:985-991.
13. Su H., Zhao J., Xiong Y., Xu T., Zhou F., Yuan Y., Zhang Y., Zhuang S.M. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China. Mutat. Res. 2008, 641:27-35.
14. Tryndyak V.P., Muskhelishvili L., Kovalchuk O., Rodriguez-Juarez R., Montgomery B., Churchwell M.I., Ross S.A., Beland F.A., Pogribny I.P. Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: implications for tamoxifen-induced hepatocarcinogenesis. Carcinogenesis 2006, 27:1713-1720.
15. Bagnyukova T.V., Tryndyak V.P., Montgomery B., Churchwell M.I., Karpf A.R., James S.R., Muskhelishvili L., Beland F.A., Pogribny I.P. Genetic and epigenetic changes in rat preneoplastic liver tissue induced by 2-acetylaminofluorene. Carcinogenesis 2008, 29:638-646.
16. Salnikow K., Zhitkovich A. Genetic and epigenetic mechanisms in metal carcinogenesis and co-carcinogenesis: nickel, arsenic, and chromium. Chem. Res. Toxicol. 2008, 21:28-44.
17. Marin-Kuan M., Cavin C., Delatour T., Schilter B. Ochratoxin A carcinogenicity involves a complex network of epigenetic mechanisms. Toxicon 2008, 52:195-202.
18. Shiao Y.H. Genetic signature for human risk assessment: lessons from trichloroethylene. Environ. Mol. Mutagen. 2009, 50:68-77.
19. Bannash P. Preneoplastic lesions as end points in carcinogenicity testing. I. Hepatic preneoplasia. Carcinogenesis 1986, 7:689-695.
20. Bannasch P., Haertel T., Su Q. Significance of hepatic preneoplasia in risk identification and early detection of neoplasia. Toxicol. Pathol. 2003, 31:134-139.
21. Grasl-Kraupp B., Luebeck G., Wagner A., Löw-Baselli A., de Gunst M., Waldhör T., Moolgavkar S., Schulte-Hermann R. Quantitative analysis of tumor initiation in rat liver: role of cell replication and cell death (apoptosis). Carcinogenesis 2000, 21:1411-1421.
22. Higashi K., Hiai H., Higashi T., Muramatsu M. Regulatory mechanism of glutathione S-transferase P-form during chemical carcinogenesis: old wine in a new bottle. Cancer Lett. 2004, 209:155-163.
23. Satoh K., Hatayama I. Anomalous elevation of glutathione S-transferase P-form (GST-P) in the elementary process of epigenetic initiation of chemical hepatocarcinogenesis in rats. Carcinogenesis 2002, 23:1193-1198.
24. Pogribny I.P., Muskhelishvili L., Tryndyak V.P., Beland F.A. The tumor-promoting activity of 2-acetylaminofluorene is associated with disruption of the p53 signaling pathway and the balance between apoptosis and cell proliferation. Toxicol. Appl. Pharmacol. 2009, 235:305-311.
25. Strauss W.M. Preparation of genomic DNA from mammalian tissue. Current Protocols in Molecular Biology 1989, 2.2.1-2.2.3. Wiley-Interscience, New York. F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, K. Struhl (Eds.).
26. Herman J.G., Graff J.R., Myöhänen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:9821-9826.
27. Asada K., Asada R., Yoshiji H., Fukui H., Floyd R.A., Kotake Y. DNA cytosine methylation profile in various cancer-related genes is altered in cultured rat hepatocyte cell lines as compared with primary hepatocytes. Oncol. Rep. 2006, 15:1241-1248.
28. Swafford D.S., Middleton S.K., Palmisano W.A., Nikula K.J., Testaigzi J., Baylin S.B., Herman J.G., Belinsky S.A. Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Mol. Cell. Biol. 1997, 17:1366-1374.
29. Niwa T., Yamashita S., Tsukamoto T., Kuramoto T., Nomoto T., Wakazono K., Fujita H., Matsushima T., Tatematsu M., Sugimura T., Ushijima T. Whole-genome analyses of loss of heterozygosity and methylation analysis of four tumour suppressor genes in N-methyl-N′-nitro-N-nitrosoguanidine-induced rat stomach carcinomas. Cancer Sci. 2005, 96:409-413.
30. De Miglio M.R., Simile M.M., Muroni M.R., Pusceddu S., Calvisi D., Carru A., Seddaiu M.A., Daino L., Deiana L., Pascale R.M., Feo F. Correlation of c-myc overexpression and amplification with progression of preneoplastic liver lesions to malignancy in the poorly susceptible Wistar rat strain. Mol. Carcinog. 1999, 25:21-29.
31. -ΔΔCt method. Methods 2001, 25:402-408.
32. Moss T.J., Wallrath L.L. Connections between epigenetic gene silencing and human disease. Mutat. Res. 2007, 618:163-174.
33. Kondo Y., Shen L., Cheng A.S., Ahmed S., Boumber Y., Charo C., Yamochi T., Urano T., Furukawa K., Kwabi-Addo B., Gold D.L., Sekido Y., Huang T.H., Issa J.P. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 2008, 40:741-750.
34. Yu Q. Cancer gene silencing without DNA hypermethylation. Epigenetics 2008, 3:315-317.
35. Martin J., Dufour J.F. Tumor suppressor and hepatocellular carcinoma. World J. Gastroenterol. 2008, 14:1720-1733.
36. Tischoff I., Tannapfe A. DNA methylation in hepatocellular carcinoma. World J. Gastroenterol. 2008, 14:1741-1748.
37. Strunnikova M., Schagdarsurengin U., Kehlen A., Garbe J.C., Stampfer M.R., Dammann R. Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter. Mol. Cell. Biol. 2005, 25:3923-3933.
38. Bagnyukova T.V., Tryndyak V.P., Muskhelishvili L., Ross S.A., Beland F.A., Pogribny I.P. Epigenetic downregulation of the suppressor of cytokine signaling 1 (Socs1) gene is associated with the STAT3 activation and development of hepatocellular carcinoma induced by methyl-deficiency. Cell Cycle 2008, 7:3202-3210.
39. Sun F., Wang J., Pan Q., Yu Y., Zhang Y., Wan Y., Wang J., Li X., Hong A. Characterization of function and regulation of miR-24-1 and miR-31. Biochem. Biophys. Res. Commun. 2009, 380:660-665.
40. Sakai M., Muramatsu M. Regulation of glutathione transferase P: a tumor marker of hepatocarcinogenesis. Biochem. Biophys. Res. Commun. 2007, 357:575-578.
41. Feinberg A.P., Ohlsson R., Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006, 7:21-33.
42. Baylin S.B., Ohm J.E. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction. Nat. Rev. Cancer 2006, 6:107-116.
43. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
44. Beland F.A., Kadlubar F.F. Metabolic activation and DNA adducts of aromatic amines and nitroaromatic hydrocarbons. Handbook of Experimental Pharmacology 1990, vol. 94/1:267-325. Springer-Verlag, Berlin.
45. Heflich R.H., Neft R.E. Genetic toxicity of 2-acetylaminofluorene, 2-aminofluorene and some of their metabolites and model metabolites. Mutat. Res. 1994, 318:73-174.
46. Neumann H.G. Aromatic amines in experimental cancer research: tissue-specific effects, an old problem and new solutions. Crit. Rev. Toxicol. 2007, 37:211-236.
47. Feinberg A.P. Epigenetics at the epicenter of modern medicine. JAMA 2008, 299:1345-1350.
48. Gopalakrishnan S., Von Emburgh B.O., Robertson K.D. DNA methylation in development and human disease. Mutat. Res. 2008, 647:30-38.
49. Pogribny I.P., Beland F.A. DNA hypomethylation in the origin and pathogenesis of human diseases. Cell. Mol. Life Sci. 2009, 66:2249-2261.
50. Kourmouli N., Jeppese P., Mahadevhaiah S., Burgoyne P., Wu R., Gilbert D.M., Bongiorni S., Prantera G., Fanti L., Pimpinelli S., Shi W., Fundele R., Singh P.B. Heterochromatin and tri-methylated lysine 20 of histone H4 in animals. J. Cell Sci. 2004, 117:2491-2501.
51. Martens J.H.A., O'Sullivan R.J., Braunschweig U., Opravil S., Radolf M., Steinlein P., Jenuwein T. The profile of repeat-associated histone lysine methylation states in the mouse epigenome. EMBO J. 2005, 24:800-812.
52. Rocco J.W., Sidransky D. p16(MTS-1/CDK2/INK4a) in cancer progression. Exp. Cell Res. 2001, 264:42-55.
53. Donninger H., Vos M.D., Clark G.J. The RASSF1A tumor suppressor. J. Cell Sci. 2007, 120:3163-3172.
54. Petrocca F., Vecchione A., Croce C.M. Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res. 2008, 68:8191-8194.
55. O'Donnell K.A., Wetzel E.A., Zeller K.I., Dang C.V., Mendell J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
56. Pogribny I.P., Tryndyak V.P., Boyko A., Rodriguez-Juarez R., Beland F.A., Kovalchuk O. Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat. Res. 2007, 619:30-37.
57. Steinmetz K.L., Pogribny I.P., James S.J., Pitot H.C. Hypomethylation of the rat glutathione S-transferase π (GSTP) promoter region isolated from methyl-deficient livers and GSTP-positive liver neoplasms. Carcinogenesis 1998, 19:1487-1494.